The Prevention of Venous Thromboembolism After Surgery for Cancer

REFERENCES

• Donati M. B. Cancer and thrombosis. Haemostasis 1994; 24: 128–131
   PubMedGoogle Scholar
• Prandoni P., Lensing A. W., Cogo A., et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1–7
   PubMed Web of Science ®Google Scholar
• Hutten B. A., Prins M. H., Gent M., et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000; 18: 3078–3083
   PubMed Web of Science ®Google Scholar
• Khorana A. A., Francis C. W., Culakova E., et al. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006; 24: 484–490
   PubMed Web of Science ®Google Scholar
• Bergqvist D. Risk of venous thromboembolism in patients undergoing cancer surgery and options for thromboprophylaxis. J Surg Oncol 2007; 95: 167–174
   PubMed Web of Science ®Google Scholar
• Levitan N., Dowlati A., Remick S. C., et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78: 285–291
   PubMed Web of Science ®Google Scholar
• Pritchard K. I., Paterson A. H., Paul N. A., et al. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized controlled trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada clinical trials group breast cancer site group. J Clin Oncol 1996; 4: 2731–2737
   Google Scholar
• Rus C., Bazzan M., Palumbo A., et al. Thalidomide in front line treatment in multiple myeloma: serioud risk of venous thromboembolism and evidence for thromboprophylaxis. J Thromb Haemost 2004; 2: 2063–2065
   PubMed Web of Science ®Google Scholar
• Walshe L. J., Malak S. F., Eagan J., et al. Complication rates among cancer patients with peripheral inserted central catheters. J Clin Oncol 2002; 20: 3276–3281
   PubMed Web of Science ®Google Scholar
• Agnelli G., Bolis G., Capussotti L., et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 2006; 243: 89–95
   PubMed Web of Science ®Google Scholar
• Nilsson K. R., Berenholtz S. M., Garrett-Mayer E., et al. Association between venous thromboembolism and perioperative allogeneic transfusion. Arch Surg 2007; 142: 126–133
   PubMed Web of Science ®Google Scholar
• Haas S., Wolf H., Kakkar A. K., et al. Prevention of fatal pulmonary embolism and mortality in surgical patients: a randomized double-blind comparison of LMWH with unfractionated heparin. Thromb Haemost 2005; 94: 814–819
   PubMed Web of Science ®Google Scholar
• Kakkar A. K., Haas S., Wolf H., et al. Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients: the MC-4 cancer substudy. Thromb Haemost 2005; 94: 867–871
   PubMed Web of Science ®Google Scholar
• Levine M., Hirsh J., Gent M., et al. Double-blind randomized trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343: 886–889
   PubMed Web of Science ®Google Scholar
• Bergqvist D., Burmark U. S., Frisell J., et al. Low-molecular-weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis. Br J Surg 1986; 73(3)204–208
   PubMed Web of Science ®Google Scholar
• Bergqvist D., Matzsch T., Burmark U. S., et al. Low-molecular-weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis. Br J Surg 1988; 75(9)888–891
   PubMed Web of Science ®Google Scholar
• Samama M., Bernard P., Bonnardot J. P., et al. Low-molecular-weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. Br J Surg 1988; 75(2)128–131
   PubMed Web of Science ®Google Scholar
• Liezorovicz A., Picolet H., Peyrieux J. C., et al. Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double blind study comparing two doses of Logiparin and standard heparin. H. B. P. M. Research Group. Br J Surg 1991; 78(4)412–416
   PubMed Web of Science ®Google Scholar
• Kakkar V. V., Cohen A. T., Edmonson R. A., et al. Low-molecular-weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The thromboprophylaxis collaborative group. Lancet 1993; 341(8840)259–265
   PubMedGoogle Scholar
• Boneu B. An international multicentre study: Clivarin in the prevention of venous thromboembolism in patients undergoing general surgery. Report of the international clivarin assessment group. Blood Coagul Fibrinolysis 1993; 4(Suppl. 1)S21–S22
   PubMedGoogle Scholar
• Anonymous. Comparison of a low-molecular-weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. The European fraxiparin study (EFS) group. Br J Surg 1988; 75(11)1058–1063
   PubMed Web of Science ®Google Scholar
• Gallus A., Cade J., Ockelford P., et al. Orgaran (Org 10172) or heparin for preventing venous thrombosis after elective surgery for malignant disease? A double-blind, randomized, multicentre comparison. ANZ-Organon investigators' group. Thromb Heamost 1993; 70(4)562–567
   PubMed Web of Science ®Google Scholar
• Nurmohamed M. T., Verhaeghe R., Haas S., et al. A comparative trial of a low–molecular-weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery. Am J Surg 1995; 169(6)567–571
   PubMed Web of Science ®Google Scholar
• ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg 1997; 84: 1099–1103
   PubMed Web of Science ®Google Scholar
• McLeod R. S., Geerts W. H., Sniderman K. W., et al. Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the Canadian colorectal DVT prophylaxis trial. A randomized, double-blind trial. Ann Surg 2001; 233: 438–444
   PubMed Web of Science ®Google Scholar
• Leonardi M. J., McGory M. L., Ko C. Y. A systematic review of deep venous thrombosis prophylaxis in cancer patients: implications for improving quality. Ann Surg Oncol 2007; 14: 929–936
   PubMed Web of Science ®Google Scholar
• Mismetti P., Laporte S., Darmon J. Y., et al. Meta-analysis of low-molecular-weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2005; 88: 913–930
   Google Scholar
• Creekmore F. M., Oderda G. M., Pendleton R. C., et al. Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism. Pharmacotherapy 2006; 26: 1438–1445
   PubMed Web of Science ®Google Scholar
• Bergqvist D., Burmark U. S., Flordal P. A., et al. Low-molecular-weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients. Br J Surg 1995; 82: 496–501
   PubMed Web of Science ®Google Scholar
• Agnelli G., Bergqvist D., Cohen A. T., et al. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 2005; 92: 1212–1220
   PubMed Web of Science ®Google Scholar
• Rosenberg I. L., Evans M., Pollock A. V. Letter: prophylaxis of postoperative deep vein thrombosis. Br Med J 1975; 3(5977)228
   PubMed Web of Science ®Google Scholar
• Roberts V. C., Cotton L. T. Prevention of postoperative deep vein thrombosis in patients with malignant disease. Br Med J 1974; 1(904)358–360
   PubMedGoogle Scholar
• Athanasoulis C. A., Kaufman J. A., Halpern E. F., et al. Inferior vena caval filters: review of a 26-year single-center clinical experience. Radiology 2000; 216(1)54–66
   PubMed Web of Science ®Google Scholar
• Bergqvist D., Agnelli G., Cohen A. T., et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002; 346: 975–980
   PubMed Web of Science ®Google Scholar
• Rasmussen M. S., Jorgensen L. N., Wille-Jorgensen P., et al. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost 2006; 4: 2384–2390
   PubMed Web of Science ®Google Scholar
• Von Tempelhoff G. F., Dierich M., Niemann F., et al. Blood coagulation and thrombosis in patients with ovarian malignancy. Thromb Haemost 1997; 77(3)456–461
   PubMed Web of Science ®Google Scholar
• Oates-Whitehead R. M., D'Angelo A., Mol B. Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynaecological surgery. Abstract retrieved from Cochrane database Syst Rev 2003, (4), CD003679
   Google Scholar
• Kibel A. S., Loughlin K. R. Pathogenesis and prophylaxis of postoperative thromboembolic disease in urological pelvic surgery. J Urol 1995; 153(6)1763–1774
   PubMed Web of Science ®Google Scholar
• Goldhaber S. Z., Dunn K., Gerhard-Herman M., et al. Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. Chest 2002; 122: 1933–1937
   PubMed Web of Science ®Google Scholar
• Iorio A., Agnelli G. Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. Arch Intern Med 2000; 160: 2327–2332
   PubMed Web of Science ®Google Scholar
• Geerts W. H., Pineo G. F., Heit J. A., et al. Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126(Suppl. 3)338S–400S
   PubMedGoogle Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Venous thromboembolic disease. V.1.2007, http://www.nccn.org/professionals/physician_gls/PDF/vte.pdf Accessed 20 January 2009
   Google Scholar
• Lyman G. H., Khorana A. A., Falanga A, et al. American Society of Clinical Oncolgy guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490–5505
   PubMed Web of Science ®Google Scholar
• Kakkar A. K., Levine M., Pinedo H. M., et al. Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist 2003; 8: 381–388
   PubMed Web of Science ®Google Scholar
• Stratton M. A., Anderson F. A., Bussey H. I., et al. Prevention of venous thromboembolism: adherence to the 1995 American College of Chest Physician consensus guidelines for surgical patients. Arch Intern Med 2000; 160: 334–340
   PubMed Web of Science ®Google Scholar